ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.996,63
0,89%
S&P 500
5.728,08
0,17%
Dow Jones
42.151,93
0,06%
Euro vs US Dollar
1,11655
0,49%
Bitcoin
63.856,05
0,83%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Elevai Labs Inc (ELAB)

  7. Elevai Labs Inc (ELAB) News

ELAB

Elevai Labs (ELAB)

Elevai Labs Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ELAB
DatumZeitQuelleÜberschriftSymbolFirma
24/09/202415h27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELABElevai Labs Inc
24/09/202415h26Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ELABElevai Labs Inc
23/09/202414h45GlobeNewswire Inc.Elevai Labs Inc. Announces Pricing of $8.0 Million Public OfferingNASDAQ:ELABElevai Labs Inc
23/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELABElevai Labs Inc
19/09/202412h13Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ELABElevai Labs Inc
10/09/202413h30GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma ApplicationsNASDAQ:ELABElevai Labs Inc
06/09/202422h45Edgar (US Regulatory)Form DEFR14C - Revised information statement materials, definitiveNASDAQ:ELABElevai Labs Inc
06/09/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELABElevai Labs Inc
04/09/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELABElevai Labs Inc
03/09/202416h25AllPennyStocks.comMicro Cap Stealing Premarket Show Before Tuesday's Opening BellNASDAQ:ELABElevai Labs Inc
03/09/202413h30GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome TechnologyNASDAQ:ELABElevai Labs Inc
28/08/202413h30GlobeNewswire Inc.Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™NASDAQ:ELABElevai Labs Inc
26/08/202421h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELABElevai Labs Inc
26/08/202414h34Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ELABElevai Labs Inc
26/08/202413h30GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome SerumNASDAQ:ELABElevai Labs Inc
24/08/202403h52Edgar (US Regulatory)Form PRER14C - Information statementsNASDAQ:ELABElevai Labs Inc
19/08/202415h00GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health ApplicationsNASDAQ:ELABElevai Labs Inc
16/08/202423h16Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ELABElevai Labs Inc
16/08/202422h10Edgar (US Regulatory)Form PRER14C - Information statementsNASDAQ:ELABElevai Labs Inc
16/08/202416h01Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ELABElevai Labs Inc
14/08/202415h05GlobeNewswire Inc.Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ELABElevai Labs Inc
14/08/202414h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELABElevai Labs Inc
05/08/202422h44Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ELABElevai Labs Inc
05/08/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELABElevai Labs Inc
02/08/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELABElevai Labs Inc
30/07/202415h00GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhDNASDAQ:ELABElevai Labs Inc
28/06/202415h00GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product LineNASDAQ:ELABElevai Labs Inc
26/06/202415h00GlobeNewswire Inc.Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024NASDAQ:ELABElevai Labs Inc
14/06/202415h00GlobeNewswire Inc.Elevai Labs Forms New Scientific Advisory Board for its Weight Loss ProgramsNASDAQ:ELABElevai Labs Inc
01/06/202402h10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELABElevai Labs Inc
 Showing the most relevant articles for your search:NASDAQ:ELAB

Kürzlich von Ihnen besucht

USOTC
RHHBY
Roche (QX)
FX
EURJPY
Euro vs Yen
NASDAQ
QQQ
Invesco QQQ Trust Series 1
COIN
DOGEUSD
Dogecoin
CCOM
SILVER
SILVER
USOTC
ADDYY
Adidas (QX)
AMEX
SPY
SPDR S&P 500
COIN
SOLUSD
Solana
FX
EURGBP
Euro vs Sterling
NASDAQ
NVDA
NVIDIA
AMEX
XLV
Health Care Select Sector
TG
DTE
Deutsche Telekom
DBI
MDAX
MDAX
USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten